Category Archives: Research and Development

Tuberculosis R&D “grossly insufficient” according to new report

By on .

The global tuberculosis response and TB research and development remain weak and inadequate despite approval of the first new TB drugs in decades and a new global strategy to reduce TB incidence and mortality, according to Treatment Action Groups’ latest report. With just $255 million spent on TB research and development each year, funding is […]

Large-scale study underscores value of routine Xpert testing on TB, MDR TB case finding

By on .

A study of more than 100,000 patients with suspected tuberculosis at 18 sites across India showed that routine testing using Xpert molecular technology rather than the most commonly used — and oldest — diagnostic tool of examining a sputum smear under a microscope, increased detection of TB by 39 percent and led to five times […]

First all-oral XDR-TB drug regimen trial launches in South Africa

By on .

The TB Alliance Wednesday announced the launch of the first clinical trial testing an all-oral regimen to treat extensively- drug resistant tuberculosis. With a three drug combination the Nix-TB regimen trial seeks to cure patients within six to nine months. The trial will launch at three sites in South Africa and will include patients as […]

Xpert use reduced wait for treatment, study shows, but health system, patient challenges remain barriers to full benefits

By on .

The demand for, and the promise of, quick accurate tools to diagnose tuberculosis, and to discover resistance to basic TB treatments, are based on a simple and seemingly irrefutable premise. Such tools, it has been pointed out, make early and effective treatment possible, benefiting both patients and public with faster and more frequent cures, and […]

A TB vaccine? GHIT Fund eyes that prize, and more as public private partnership takes off

By on .

What does it take to move research from recognition of need to realization? Increasingly, in a funding landscape that has seen an actual decline in dollars to develop new tools for tuberculosis along with other diseases, the answer has been public-private partnerships. The most recent prominent example is the Global Health Innovative Technology — GHIT […]

TB vaccine trial: “A stepping stone on a very long journey”

By on .

In the wake of announcing clinical trial results that showed  a candidate for a tuberculosis vaccine was safe, but did not protect babies from infection and disease, researchers are emphasizing what they have learned, and how it might yet pave the way for a long-term answer to the epidemic. The trial of MVA85A, a candidate […]

FDA TB drug approval a milestone, with caveats

By on .

The U.S. Food and Drug Administration’s approval of the first new drug to treat tuberculosis in nearly half a century and the agency’s first use of its accelerated approval process to speed availability of TB medicine comes with cautions, and with a direction of work yet to be done, agency officials and treatment advocates agree. […]

FDA panel finds new type of TB drug effective, raising hopes for treatment of drug-resistant strains

By on .

Dr. Dalene von Delft had a choice between dying  or going deaf, and that was a choice only if the arduous treatment she was undergoing for drug-resistant tuberculosis worked. The South African pediatrician had contracted a resistant strain of the disease caring for patients, and the only potentially effective treatment was showing one of its […]

Good Participatory Practice TB drug trial guidelines lay groundwork for research, use of new treatments

By on .

If you consider all the years that time stood still in the world of tuberculosis drug research, the most compelling aspect of the Good Participatory Practice Guidelines for TB Drug Trials just released by a Critical Paths to TB Drug Regimens working group is that occasions exist for them to be used. With nearly half […]

TB drug trial yields gains in drug-resistant disease treatment

By on .

A study following patients who had  participated in a trial of a potential new treatment for drug-resistant tuberculosis has shown heartening results, with nearly three-quarters of patients who took the medicine for six months or longer showing “favorable outcomes”  — cured  or completed treatment —  according to a study published in the European Respiratory Journal. […]